AlphaStreet Newsdesk powered by AlphaStreet Intelligence
Humacyte, Inc. (HUMA) reported Q1 2026 internet loss per share, diluted, of $0.09 per share, a narrower loss than the -$0.12 estimate (25.0% narrower). The corporate generated $495,000 in income for the quarter, which was down 4.3% from the $517,000 recorded in Q1 2025.
Humacyte, Inc. is a Biotechnology firm. Symvess product income was $493,000 for the quarter. The corporate operated 29 Items of Symvess bought at quarter finish. Backside line confirmed a internet lack of $17.6M.
Wall Avenue consensus stands at 8 purchase, 2 maintain, 0 promote. EPS was down 132.1% from $0.28 in Q1 2025.
An in depth evaluation of Humacyte, Inc.’s quarter follows shortly on AlphaStreet.
This content material is for informational functions solely and shouldn’t be thought-about funding recommendation. AlphaStreet Intelligence analyzes monetary knowledge utilizing AI to ship quick and correct market info. Human editors confirm content material.
